Loading...

dumbcritic's Recent CancerCompass Activity

  • dumbcritic has replied to a post on the message board

    MCT2 has been documented in multiple cancer types [1], and may compensate for inhibition of MCT1 and/or MCT4. So targeting that could help, as well as OXPHOS [2]. Refs: 1 https://www.hindawi.com/journals/bmri/2010/427694/ 2 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3590

    April 11 at 3:02 AM view post
    • dumbcritic has replied to a post on the message board

      A second https://www.abstractsonline.com/pp8/#!/9325/presentation/2353

      April 11 at 2:48 AM view post
      • dumbcritic has replied to a post on the message board

        The poster https://www.sdponcology.com/_assets/static/poster_sdpo_tp-1454_aacr-2021.pdf Also, some more preclinical data https://mct.aacrjournals.org/content/18/12_Supplement/B080

        April 11 at 2:46 AM view post
        • dumbcritic has replied to a post on the message board

          An oral PKM2 activator is now in the clinic https://www.abstractsonline.com/pp8/#!/9325/presentation/1500

          April 11 at 2:43 AM view post
          • dumbcritic has replied to a post on the message board

            A new synthetic small molecule, which is a pan-class I GLUT inhibitor https://cancerandmetabolism.biomedcentral.com/articles/10.1186/s40170-021-00248-7 An older paper (using a different small molecule plus CB-839) https://www.sciencedirect.com/science/article/pii/S2451945619302065

            March 27 at 6:34 PM view post
            • dumbcritic has replied to a post on the message board

              Yes, not only is the second point true, but deregulated metabolism is arguably one of the more important of the ten hallmarks, and far more homogeneous across different types and stages than genome instability, which varies from cell to cell, between tumours, and person to person https://www.nejm.org/doi/full/10.1056/nejmoa1113205 We know that dual inhibition of MCT1 and MCT4 would likely synergise when combined w...

              March 13 at 11:03 PM view post
              • dumbcritic has replied to a post on the message board

                Nirogy Therapeutics lead program is a dual MCT1/4 inhibitor, which should enter into clinical trials next year https://www.abstractsonline.com/pp8/#!/9325/presentation/2388

                March 11 at 10:12 PM view post
                • dumbcritic has replied to a post on the message board

                  Vidac Pharma has announced the inclusion of the first patient in a placebo controlled PhII trial for early forms of CTCL treated with its first-in-class drug VDA-1102. This disrupts the binding of HK2 from VDAC. 

                  February 20 at 10:41 PM view post
                  • dumbcritic has replied to a post on the message board

                    A new company, who will be in the clinic soon https://penrosetherapeutx.com/science-and-pipeline/

                    February 19 at 2:40 AM view post
                    • dumbcritic has replied to a post on the message board

                      Early human data in patients with refractory CRC [1] and more info on the drug itself [2]. Refs: 1 https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e16027 2 http://www.metimedi.com/science/cancermetabolism.php

                      July 15 at 11:29 PM view post
                      Loading...
                      Load more activity
                      Loading more activity

                      About dumbcritic

                      dumbcritic has not shared any information about themselves. Send them a message to tell them you'd like to find out more about them or add them as a friend.

                      We care about your feedback. Let us know how we can improve your CancerCompass experience.